Skip to main content
. Author manuscript; available in PMC: 2021 May 19.
Published in final edited form as: Leukemia. 2019 Aug 22;34(1):35–49. doi: 10.1038/s41375-019-0531-8

Fig. 7.

Fig. 7

Anti-IL-7Rα is effective in controlling the growth of chemotherapy resistant leukemia in NOD.SCID mice. a Experimental protocol. Patient derived T-ALL xenografts were established by intravenous injection into 20 NOD.SCID mice on day 0. When leukemia burden reached 1% in peripheral blood, mice were treated with a combination of dexamethasone (5 mg/kg, daily) and vincristine (0.15 mg/kg, weekly) for 4 weeks. On day 69, mice were given a single intravenous injection of anti-IL-7Rα 4A10 and 2B8 (250 μg of each MAb) or PBS on day 69. b Chemotherapy resistant leukemia was detected in the blood of mice at day 61 (n = 3). c Growth of chemotherapy resistant leukemia was controlled by a single injection of anti-human IL-7Rα 4A10 combined with 2B8 at day 75 compared to mice that received chemo alone (n = 2)